Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

Completed · Phase 2

Conditions studied: Carcinoma, Non-small-cell Lung

In brief

The purpose of this study is to learn about the effects of two new anticancer drugs, erlotinib (Tarceva) and bexarotene (Targretin), when treating patients with advanced lung cancer. Erlotinib is approved by the Food and Drug Administration (FDA) for the treatment of non-small-cell lung cancer (NSCLC). Bexarotene is approved by the FDA for the treatment of cutaneous T-cell lymphoma. This combination of drugs is experimental.

Key facts

Study ID

NCT00125359

Run by

Konstantin Dragnev

People needed

42

Starts

2005-08-01

Expected to finish

2014-03-01

Last updated by the study team

2019-01-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Advanced NSCLC
• Prior chemotherapy or radiotherapy is allowed.

You may not qualify if…

• Hepatic or renal dysfunction

Where it is running

• Norris Cotton Cancer Center — Lebanon, New Hampshire, United States
• Mount Sinai School of Medicine — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.